{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:44:06Z","timestamp":1780465446084,"version":"3.54.1"},"reference-count":39,"publisher":"Charles University in Prague, Karolinum Press","issue":"1","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Prague Med. Rep."],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>Alopecia areata is a disease of autoimmune origin which causes non scarring hair loss. The extent of alopecia varies from a small patch to complete scalp and body hair loss, which can have huge psychosocial impact for those affected. Treatment modalities which have been used so far included nonspecific immunosuppressive medications, such as corticosteroids, cyclosporine, and methotrexate, or topical immunomodulators, such as diphencyprone, dithranol, and squaric acid dibutylester. The recognition of the importance of Janus kinase pathway in alopecia areata pathogenesis enabled more specific approaches in treatment. Positive outcomes of Janus kinase inhibitors in several trials granted approval for baricitinib which became the first on-label treatment for alopecia areata. The aim of this review is to summarize the role, efficacy and safety of several Janus kinase inhibitors in alopecia areata.<\/jats:p>","DOI":"10.14712\/23362936.2023.1","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T14:50:19Z","timestamp":1676040619000},"page":"5-15","source":"Crossref","is-referenced-by-count":10,"title":["Janus Kinase Inhibitors in the Treatment of Alopecia Areata"],"prefix":"10.14712","volume":"124","author":[{"given":"Athanasios J.","family":"Stefanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5727","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"23362936.2023.1_1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaad.2009.10.031","volume":"62","author":"Alkhalifah","year":"2010","journal-title":"Treatment. J. Am. Acad. Dermatol."},{"key":"23362936.2023.1_2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/intimm\/dxz039","volume":"31","author":"Anzai","year":"2019","journal-title":"Int. Immunol."},{"key":"23362936.2023.1_3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","volume":"77","author":"Bayart","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"23362936.2023.1_4","unstructured":"ClinicalTrials.gov (2022) Long-term PF-06651600 for the treatment of alopecia areata (ALLEGRO-LT). Accessed June 25, 2022. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04006457"},{"key":"23362936.2023.1_5","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/jid.2014.260","volume":"134","author":"Craiglow","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"23362936.2023.1_6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/ijt.ijt_99_17","volume":"10","author":"Darwin","year":"2018","journal-title":"Int. J. Trichology"},{"key":"23362936.2023.1_7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2147\/CCID.S309215","volume":"25","author":"Dillon","year":"2021","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"23362936.2023.1_8","unstructured":"European Medicines Agency (2017) Olumiant. Updated June 29, 2022. Accessed August 26, 2022. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant"},{"key":"23362936.2023.1_9","unstructured":"European Medicines Agency (2017) Xeljanz. Updated July 8, 2022. Accessed September 5, 2022. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xeljanz"},{"key":"23362936.2023.1_10","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology"},{"key":"23362936.2023.1_11","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1468-3083.2006.01676.x","volume":"20","author":"Goh","year":"2006","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"23362936.2023.1_12","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci. Rep."},{"key":"23362936.2023.1_13","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","volume":"138","author":"Jabbari","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"23362936.2023.1_14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1753495X211056211","volume":"15","author":"Jorgensen","year":"2022","journal-title":"Obstet. Med."},{"key":"23362936.2023.1_15","first-page":"e89776","volume":"1","author":"Kennedy","year":"2016","journal-title":"JCI Insight"},{"key":"23362936.2023.1_16","doi-asserted-by":"crossref","first-page":"e001374","DOI":"10.1136\/rmdopen-2020-001374","volume":"6","author":"Kerschbaumer","year":"2020","journal-title":"RMD Open"},{"key":"23362936.2023.1_17","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"King","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"23362936.2023.1_18","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.7573\/dic.2021-11-4","volume":"11","author":"Liu","year":"2022","journal-title":"Drugs Context"},{"key":"23362936.2023.1_19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"Liu","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"23362936.2023.1_20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jaad.2017.10.043","volume":"78","author":"Liu","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"23362936.2023.1_21","doi-asserted-by":"crossref","first-page":"101606","DOI":"10.1016\/j.bpg.2019.03.002","volume":"38\u201339","author":"Ma","year":"2019","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"23362936.2023.1_22","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"23362936.2023.1_23","unstructured":"National Center for Biotechnology Information (2022) PubChem Compound Summary for CID 44205240, Baricitinib. Accessed November 27, 2022. Available at: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound \/Baricitinib"},{"key":"23362936.2023.1_24","unstructured":"National Center for Biotechnology Information (2022) PubChem Compound Summary for CID 25126798, Ruxolitinib. Accessed November 27, 2022. Available at: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound \/Ruxolitinib"},{"key":"23362936.2023.1_25","unstructured":"National Center for Biotechnology Information (2022) PubChem Compound Summary for CID 9926791, Tofacitinib. Accessed November 27, 2022. Available at: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound \/Tofacitinib"},{"key":"23362936.2023.1_26","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/bjd.17142","volume":"179","author":"Ohyama","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"23362936.2023.1_27","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jaad.2019.10.016","volume":"82","author":"Olsen","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"23362936.2023.1_28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1087-0024.2003.00807.x","volume":"8","author":"Paus","year":"2003","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"23362936.2023.1_29","unstructured":"Pfizer (2021) Pfizer announces positive top-line results from phase 2b\/3 trial of ritlecitinib in alopecia areata. Press release. Accessed June 20, 2022. Available at: https:\/\/www.pfizer.com\/news\/press-release \/press-release-detail\/pfizer-announces-positive-top-line-results-phase-2b3-trial"},{"key":"23362936.2023.1_30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2147\/DDDT.S334727","volume":"16","author":"Ram\u00edrez-Mar\u00edn","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"23362936.2023.1_31","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nri2580","volume":"9","author":"Rochman","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"23362936.2023.1_32","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jcph.354","volume":"54","author":"Shi","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"23362936.2023.1_33","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2147\/DDDT.S172638","volume":"12","author":"Triyangkulsri","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"23362936.2023.1_34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/ijt.ijt_62_18","volume":"10","author":"Trueb","year":"2018","journal-title":"Int. J. Trichology"},{"key":"23362936.2023.1_35","unstructured":"U.S. Food and Drug Administration (2022) FDA Approves First Systemic Treatment for Alopecia Areata. Released June 13, 2022. Updated June 13, 2022. Accessed June 22, 2022. Available at: https:\/\/ www.fda.gov\/news-events\/press-announcements\/fda-approves-first-systemic-treatment-alopecia-areata"},{"key":"23362936.2023.1_36","first-page":"397","volume":"8","author":"Villasante","year":"2015","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"23362936.2023.1_37","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/1346-8138.14283","volume":"45","author":"Wa\u015bkiel","year":"2018","journal-title":"J. Dermatol."},{"key":"23362936.2023.1_38","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/jdv.17909","volume":"36","author":"Winnette","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"23362936.2023.1_39","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","volume":"61","author":"Zhou","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."}],"container-title":["Prague Medical Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pmr.lf1.cuni.cz\/media\/pdf\/pmr_2023124010005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pmr.lf1.cuni.cz\/media\/pdf\/pmr_2023124010005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T09:42:05Z","timestamp":1779961325000},"score":1,"resource":{"primary":{"URL":"https:\/\/pmr.lf1.cuni.cz\/124\/1\/0005\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023]]}},"alternative-id":["pmr_2023124010005"],"URL":"https:\/\/doi.org\/10.14712\/23362936.2023.1","relation":{},"ISSN":["1214-6994","2336-2936"],"issn-type":[{"value":"1214-6994","type":"print"},{"value":"2336-2936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]}}}